| 1.375 0.035 (2.61%) | 09-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.61  |
1-year : | 1.88 |
| Resists | First : | 1.38 |
Second : | 1.61 |
| Pivot price | 1.28 |
|||
| Supports | First : | 1.21 |
Second : | 1.11 |
| MAs | MA(5) : | 1.3 |
MA(20) : | 1.27 |
| MA(100) : | 1.26 |
MA(250) : | 1.29 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 84.7 |
D(3) : | 71.6 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 1.87 | Low : | 1.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PMVP ] has closed above the upper band by 0.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 26.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.39 | 1.39 - 1.4 |
| Low: | 1.33 - 1.33 | 1.33 - 1.34 |
| Close: | 1.37 - 1.38 | 1.38 - 1.39 |
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
Tue, 08 Sep 2026
symbol__ Stock Quote Price and Forecast - CNN
Tue, 08 Sep 2026
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com
Tue, 08 Sep 2026
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - Yahoo Finance
Fri, 04 Sep 2026
Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - kalkine.ca
Tue, 01 Sep 2026
What's Going On With PMV Pharmaceuticals Stock Tuesday? - PMV Pharmaceuticals (NASDAQ:PMVP) - Benzinga
Mon, 31 Aug 2026
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 45.6 (%) |
| Shares Short | 2,240 (K) |
| Shares Short P.Month | 2,420 (K) |
| EPS | -1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.4 % |
| Return on Equity (ttm) | -71 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -0.97 |
| PEG Ratio | 0 |
| Price to Book value | 1.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|